First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: Updated results and biomarker analysis from the ASTRUM-005 randomized clinical trial.

Cancer Commun (Lond) · 2025 · PMC12365545 · PMID 40440184

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Compared to the placebo group, patients treated with serplulimab plus chemotherapy who harbored RB1 mutations showed a trend toward a higher response rate, longer PFS, and longer OS (Supplementary Figure S6 ; Supplementary Table S14 and S15 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.